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Influence of microRNA deregulation on
chaperone-mediated autophagy and a-synuclein
pathology in Parkinson’s disease
L Alvarez-Erviti1, Y Seow2, AHV Schapira1, MC Rodriguez-Oroz3,4, JA Obeso3 and JM Cooper*,1
The presence of a-synuclein aggregates in the characteristic Lewy body pathology seen in idiopathic Parkinson’s disease (PD),
together with a-synuclein gene mutations in familial PD, places a-synuclein at the center of PD pathogenesis. Decreased levels of
the chaperone-mediated autophagy (CMA) proteins LAMP-2A and hsc70 in PD brain samples suggests compromised a-
synuclein degradation by CMA may underpin the Lewy body pathology. Decreased CMA protein levels were not secondary to the
various pathological changes associated with PD, including mitochondrial respiratory chain dysfunction, increased oxidative
stress and proteasomal inhibition. However, decreased hsc70 and LAMP-2A protein levels in PD brains were associated with
decreases in their respective mRNA levels. MicroRNA (miRNA) deregulation has been reported in PD brains and we have
identified eight miRNAs predicted to regulate LAMP-2A or hsc70 expression that were reported to be increased in PD. Using a
luciferase reporter assay in SH-SY5Y cells, four and three of these miRNAs significantly decreased luciferase activity expressed
upstream of the lamp-2a and hsc70 30UTR sequences respectively. We confirmed that transfection of these miRNAs also
decreased endogenous LAMP-2A and hsc70 protein levels respectively and resulted in significant a-synuclein accumulation.
The analysis of PD brains confirmed that six and two of these miRNAs were significantly increased in substantia nigra compacta
and amygdala respectively. These data support the hypothesis that decreased CMA caused by miRNA-induced downregulation
of CMA proteins plays an important role in the a-synuclein pathology associated with PD, and opens up a new avenue to
investigate PD pathogenesis.
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Parkinson’s disease (PD) is a progressive neurodegenerative
disorder characterized pathologically by the loss of dopami-
nergic neurons in the substantia nigra pars compacta (SNc)
and the presence of Lewy bodies (LBs) that contain
aggregates of a-synuclein protein.1 The finding of mutations2
and multiplications3 of the a-synuclein gene in familial forms of
PD and the genome-wide association studies linking the a-
synuclein gene to sporadic PD4 further reinforces the
importance of a-synuclein in PD pathogenesis. The accumu-
lation and aggregation of a-synuclein in PD may reflect
changes to its synthesis and/or degradation. Although
increased a-synuclein gene copy number3 supports the role
of increased a-synuclein synthesis in PD, there is increasing
evidence that the degradation pathways responsible for
a-synuclein turnover may also be compromised in PD.5,6
Many cytosolic proteins are targeted for degradation in
lysosomes by chaperone-mediated autophagy (CMA).7 In this
pathway, a pentapeptide motif (KFERQ) present in the protein
is recognized by the heat shock cognate protein 70 (hsc70)
chaperone and internalized into the lysosome by the
membrane receptor lysosomal-associated membrane protein
2A (LAMP-2A).8 a-Synuclein contains a pentapeptide
sequence (VKKDQ) demonstrated to target it to the lyso-
some5 and, in cells, we6 and others9 have confirmed that
inhibition of CMA through downregulation of LAMP-2A protein
levels leads to a-synuclein accumulation. The relevance of
this mechanism to a-synuclein pathology in PD has been
emphasized by our recent observation that LAMP-2A and
hsc70 proteins were decreased in the SNc and amygdala in
PD brains compared with both age-matched controls and
brain samples from Alzheimer’s patients.6 Consequently, it is
important to understand the mechanism that leads to the
decrease in these CMA proteins in PD patients.
A mechanism that has been suggested to play an important
role in the regulation of up to a third of coding mRNAs involves
the expression of microRNAs (miRNAs), which are single-
stranded RNA molecules of between 21 and 23 nucleotides in
length.10 Many different miRNAs have been identified and
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shown to down-regulate protein translation or promote
degradation of specific mRNA molecules through association
with the RNA-induced silencing complex.11 miRNAs are
involved in the normal function of eukaryotic cells and miRNA
deregulation has been associated with various diseases.12 A
recent expression analysis of 224 miRNAs in PD brains
showed significant variation in the level of many miRNAs in
comparison with controls,13 suggesting that miRNA dereg-
ulation may play a role in PD pathology.
PD is also associated with a range of other biochemical
changes in the brain, the most consistent including oxidative
stress, mitochondrial dysfunction and decreased proteasomal
function. Consequently, we have investigated whether these
pathological changes or changes in miRNA levels underpin
the decreased levels of CMA proteins observed in PD brains
and can cause the a-synuclein accumulation characteristic of
PD pathology.
Results
To investigate whether biochemical features associated with
PD influenced LAMP-2A or hsc70 levels, normal SH-SY5Y
cells were exposed to conditions previously demonstrated to
induce oxidative stress (50 and 100mM paraquat), mitochon-
drial dysfunction (100, 200 nM rotenone) or proteasome
dysfunction (5 and 10 nM epoxomycin), but in the absence
of marked cell death (Supplementary Figure 1a).14,15 None of
these conditions significantly affected LAMP-2A or hsc70
protein (Figures 1a and b) or mRNA levels (Figure 1c) in
normal SH-SY5Y cells. a-Synuclein protein levels in normal
SH-SH5Y cells are not readily detectable, consequently to
determine the effect of these stresses on a-synuclein levels a
stable cell line overexpressing wild-type (WT) a-synuclein was
exposed to optimal concentrations of these agents (5 nM
epoxomycin, 100mM paraquat or 200 nM rotenone) for 48 h.
Confirming the previous experiments, LAMP-2A and hsc70
protein levels were unaltered (Figures 1d and e); however all
three treatments caused a significant increase in a-synuclein
protein levels (Figures 1d and f). This was only associated
with increased a-synuclein mRNA levels with epoxomycin
treatment (Figure 1f), suggesting UPS inhibition increased a-
synuclein transcription. To determine if this increase in
transcription was also observed for the endogenous a-
synuclein gene, normal SH-SY5Y and SKMEL-28 cells were
treated with these agents. There was no effect on endogen-
ous a-synuclein mRNA expression with any of these agents
(Supplementary Figure 1b). This suggested that proteasome
inhibition influenced the transcriptional regulation of exogen-
ous a-synuclein under the control of the cytomegalovirus
(CMV) promoter but did not influence endogenous a-synuclein
regulation.
Using the miRBase Target (Sanger Institute, Cambridge,
UK) database, we analyzed the miRNAs evaluated by Kim
et al.13 to identify which of the miRNAs expressed in brain
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Figure 1 Influence of pathological features associated with PD on LAMP-2A, hsc70 and a-synuclein levels. (a–c) Normal SH-SY5Y cells after 48 h of treatment with
different concentrations of epoxomycin (E), paraquat (P), rotenone (R) or untreated (C). (a) Western blot analyses of hsc70, LAMP-2A and actin. (b) Quantitation of the
western blot data for LAMP-2A (open bars) and hsc70 (closed bars) protein levels relative to actin and normalized to untreated cells. (c) qPCR analysis of hsc70 and LAMP-2A
mRNA relative to actin mRNA and normalized to untreated cells. (d–f) SH-SY5Y cells overexpressing WT a-synuclein after 48 h of exposure to epoxomycin (E, 5 nM),
paraquat (P, 100mM), rotenone (R, 200 nM) or under normal conditions (C). (d) Western blot analyses and (e) quantitation of the western blot data for LAMP-2A (open bars)
and hsc70 (closed bars) protein levels relative to actin and normalized to untreated (control) cells. (f) Quantitation of the western blot data for a-synuclein protein relative to
actin and mRNA levels relative to actin mRNA; all data normalized to untreated (control) cells. Data expressed as mean±S.E.M. (n¼ 3), and statistical analyses compared
with the respective control group, *Po0.05
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were predicted to target the 30 untranslated region (30UTR)
region of lamp-2a or hsc70 mRNA in humans. Although lamp-
2a, lamp-2b and lamp-2c have common exons, they differ in
their 30UTRs and exon 9,16,17 and therefore will be differen-
tially influenced by specific miRNAs. Four miRNAs strongly
predicted to target lamp-2a mRNA (hsa-miR-224; hsa-miR-
320a; hsa-miR-373*; and hsa-miR-379), and two predicted to
target hsc70 mRNA (hsa-miR-26b and hsa-miR-106a*;
Table 1) were reported to be increased in PD brains.13 In
addition, we used miRBase to identify which of the miRNAs
reported to be expressed in the brain, but not previously shown
to be increased in PD,13 gave the highest target prediction for
lamp-2a (hsa-miR-21) or hsc70 (hsa-miR-301b).
To determine the ability of these miRNAs to target the 30UTR
sequences of lamp-2a or hsc70, two luciferase reporter
constructs were generated in psiCheck2.2 with the 30UTR
sequence for either hsc70 or lamp-2a (Figure 2a). SH-SY5Y
cells were transfected with these luciferase constructs and
increasing concentrations (0–50 nM) of two different miRNAs
predicted to target the 30UTR of either hsc70 (hsa-miR-106a*)
or lamp-2a (hsa-miR-224). After 48 h, the analysis of luciferase
activity demonstrated that hsa-miR-106a* and hsa-miR-224
caused dose-dependent decreases in the activity of luciferase
with the hsc70 and lamp-2a 30UTRs, respectively (Figure 2b).
However, as a negative control, even at the higher concentra-
tions, these miRNAs had no effect on the luciferase activity
linked to the alternative 30UTR sequences (Figure 2b). Using
10 nM miRNAs to minimize nonspecific effects, four miRNAs
(hsa-miR-21*; hsa-miR-224; hsa-miR-373*; and hsa-miR-379)
and three miRNAs (hsa-miR-26b; hsa-miR-106a*; and hsa-
miR-301b) significantly decreased the luciferase activity linked
to lamp2a and hsc70 30UTRs, respectively (Figure 2c).
However, hsa-miR-320a, which was predicted to target the
30UTR of lamp-2a, did not affect the luciferase activity linked to
lamp-2a 30UTR. As an additional control, the specificity of the
miRNAs for the predicted lamp2a or hsc70 30UTR sequences
were confirmed for miRNAs hsa-miR-373*, hsa-miR-379*, hsa-
miR-106a* and hsa-miR-301b using the luciferase constructs
where the putative recognition sequence was mutated
(Supplementary Figure 2a).
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Figure 2 Luciferase reporter assays to analyze the influence of miRNAs on the 30UTR of lamp-2a and hsc70. (a) Schematic representation of the Renilla luciferase
reporter constructs in psiCHECK2.2 for lamp-2a and hsc70 30UTR. (b) The influence of increasing concentrations of hsa-miR-106a* and hsa-miR-224 on Renilla luciferase
activity when cotransfected with luciferase-30UTR hsc70 or luciferase-30UTR lamp-2a constructs. (c) The effect of cotransfection of the different miRNAs (10 nM) with either
luciferase-30UTR hsc70 or luciferase-30UTR lamp-2a reporter constructs upon Renilla luciferase activity 48 h after transfection. Data normalized to cells in the absence of
miRNA (C). Values are mean±S.E.M. (n¼ 6), statistical analyses compared with the respective control group, *Po0.05, **Po0.01, ***Po0.001
Table 1 miRNA sequences used in this study, predicted score based on the analysis of their potential to target LAMP-2A or hsc70 mRNA using the miRBase Target
(Sanger Institute) database and their predicted alamp2a or bhsc70 30UTR target sequence
microRNA Score Sequence Target sequence
hsa-miR-21* 17.40 CAACACCAGUCGAUGGGCUGU CATTTCACTACTGGTGTTa
hsa-miR-379 17.29 UGGUAGACUAUGGAACGUAGG CAATGTTTTAAGGTCTATCa
hsa-miR-373* 16.67 ACUCAAAAUGGGGGCGCUUUCC AATCCCAGCATTTTGAGa
hsa-miR-320a 16.56 AAAAGCUGGGUUGAGAGGGCGA GUCAAAACAAAGCAGCUUUa
hsa-miR-224 16.21 CAAGUCACUAGUGGUUCCGUU GGACTATAGTGATTTa
hsa-miR-301b 19.35 CAGUGCAAUGAUAUUGUCAAAGC GGAAATAACATTGCACTb
hsa-miR-26b 18.52 UUCAAGUAAUUCAGGAUAGGU ATTCTCAATACTTGAAb
hsa-miR-106a* 17.40 CUGCAAUGUAAGCACUUCUUAC GGGGAAGGAAATAACATTGCAb
Autophagy and microRNAs in Parkinson’s decrease
L Alvarez-Erviti et al
3
Cell Death and Disease
Increasing concentrations (5,10 and 50 nM) of the eight
miRNAs under investigation were transfected into normal SH-
SY5Y cells and their impact on endogenous LAMP-2A or
hsc70 protein levels evaluated. Consistent with the luciferase
reporter assays, 7 of the miRNAs resulted in a dose-
dependent decrease in either LAMP-2A or hsc70 protein
levels at 10 and 50 nM, whereas the remaining miRNA (hsa-
miR-320a) had no effect even at 50 nM (Supplementary
Figure 2b). For subsequent studies, the 7 effective miRNAs
were used at 10 nM, predicted to give a 30–70% decrease in
protein levels. After transfection of normal SH-SY5Y cells with
the 7 selected miRNAs (10 nM, 72 h), the 3 miRNAs predicted
to target hsc70 and the 4 miRNAs predicted to target lamp-2a
all decreased the levels of the respective proteins relative to
actin (Figures 3a and b), but these were only statistically
significant for hsa-miR-106a* and hsa-miR-301 (hsc70
protein) and hsa-miR-224, hsa-miR-373* and hsa-miR-379
(LAMP-2A protein). There were no changes to the levels of
lamp-2a or hsc70 mRNA relative to actin mRNA
(Supplementary Figure 3a). The impact of these changes on
intracellular a-synuclein levels was analyzed using SH-SY5Y
cells overexpressing a-synuclein and an extended 9-day
protocol. The absence of 30UTR sequences with the over-
expressed a-synuclein excluded any direct influences of the
miRNAs on a-synuclein regulation and the analysis after 9
days permitted sufficient time for the influence of decreased
CMA proteins and altered a-synuclein turnover rates to be
detected. Using this protocol the miRNA-dependent decrease
in hsc70 and LAMP-2A protein levels reported in the normal
SH-SY5Y cells were replicated in the a-synuclein overexpres-
sing cells (Figures 3c and d). In addition, as a control, the
miRNAs predicted to target lamp-2a or hsc70 had no influence
on hsc70 or LAMP-2A protein levels respectively, confirming
the relative specificity of these miRNAs at these concentra-
tions (Figures 3c and d). a-Synuclein protein levels increased
significantly in response to all the miRNAs tested (Figures 3c
and d). Although a-synuclein mRNA levels did not change
significantly for most of the miRNAs used (Supplementary
Figure 3b), hsa-miR-106a* and hsa-miR-301b caused a
significant decrease in a-synuclein mRNA levels
(Supplementary Figure 3b). These miRNAs also caused a
decrease in endogenous a-synuclein mRNA (Supplementary
Figure 3a), suggesting they may target a-synuclein tran-
scripts. Indeed hsa-miR-106a* is predicted to target the
30UTR of a-synuclein with a miRBase Target predicted score
of 15.22. The absence of increased a-synuclein transcript
levels suggests that upregulation of miRNAs predicted to
target specific CMA proteins were sufficient to result in
intracellular a-synuclein protein accumulation.
We previously reported a significant decrease in the CMA
proteins LAMP-2A and hsc70 in PD SNc and amygdala
samples.6 To determine if increased miRNA levels could be
responsible for these changes, we analyzed the levels of the
miRNAs shown to influence these proteins in control and PD
SNc and amygdala samples matched for post-mortem delay
(mean (S.D.): control, 4.8 (2.1) h; PD, 4.1 (3.0) h) and age
(mean (S.D.): control, 70.2 (6.9) years; PD, 76.6 (3.4) years,
Supplementary Table 1).
The levels of the three miRNAs targeting lamp-2a (hsa-
miR-21*; hsa-miR-224; and hsa-miR-373*) and the three
miRNAs targeting hsc70 (hsa-miR-26b; hsa-miR-106a*; and
hsa-miR-301b) were significantly increased in PD SNc
relative to actin mRNA levels (Figure 4a). These increases
corresponded to a significant decrease in lamp-2a (71%) and
hsc70 (78%) mRNA levels (Figure 4c) and a concomitant
decrease in LAMP-2A (45%) and hsc70 (51%) protein levels
previously reported.6 Similar but milder changes were
observed in PD amygdala where there was a significant
increase in the two miRNAs targeting lamp-2a (hsa-miR-224
and hsa-miR-373*) and a nonsignificant increase in the two
miRNAs targeting hsc70 (hsa-miR-26b and hsa-miR-106a*;
Figure 4b). These were associated with a mild decrease in
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Figure 3 Impact of increased miRNA levels upon LAMP-2A, hsc70 and a-synuclein protein levels. (a and b) Western blot analyses of normal SHSY5Y cells 72 h after
transfection with the respective miRNAs (10 nM) and untreated cells (C) for (a) LAMP-2A, hsc70 and actin (b) and their quantitation. (c and d) Western blot analyses of a-
synuclein overexpressing cells 9 days after treatment with miRNAs (10 nM) for (c) a-synuclein, LAMP-2A, hsc70 and actin. (d) Quantitation of a-synuclein, LAMP-2A and
hsc70 protein levels. Values are relative to actin and normalized to untreated (control) cells. Data expressed as mean±S.E.M. (n¼ 3), statistical analyses compared with the
respective control group, *Po0.05
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LAMP-2A (36%) and hsc70 (32%) protein levels6 and a mild
downregulation of lamp-2a (30%) and hsc70 (10%) mRNA
levels (Figure 4c). The changes in miRNA levels were
confirmed when the data were analyzed relative to gapdh
mRNA (Supplementary Figures 4a and b).
In SNc, the decrease in lamp-2a mRNA (71%) exceeded
the decrease in protein levels (45%); however, this was not
the situation in the amygdala (30 versus 35%). To determine
if increasing concentrations of miRNAs could account for
this difference, we evaluated the impact of increasing
concentrations of hsa-miR-373* on the mRNA and
protein levels of LAMP-2A. Relatively low miRNA concentra-
tions (10 nM) reduced LAMP-2A protein levels but had
no impact on mRNA levels, whereas higher concentrations
(50 and 100 nM) downregulated both LAMP-2A protein
and mRNA levels (Figure 4d). These data are in agreement
with the high levels of miRNA in the SNc leading to
lamp-2a mRNA degradation, whereas in the amygdala the
milder increase in miRNA concentrations had less impact
on mRNA stability.
We detected a significant decrease in a-synuclein mRNA
levels in both the SNc and amygdala samples from PD patients
(Figure 4c), in agreement with previous studies.18,19 Although
a-synuclein aggregates accumulate in LBs, we found that the
levels of SDS-soluble a-synuclein monomer were not changed
in the amygdala (Supplementary Figure 4d).20 This is
consistent with the suggestion that a-synuclein monomer
levels may be sustained, despite a decrease in transcripts,
through a decrease in its degradation via CMA.
Discussion
a-Synuclein aggregation and the formation of LBs are
characteristic pathological features of sporadic PD, but the
underlying biochemical abnormality responsible remains
to be defined. Multiplication of the a-synuclein locus is a
rare cause of familial PD but suggests that increased
synthesis of a-synuclein is sufficient to cause the disease.3
However, decreased a-synuclein degradation leading to
a-synuclein accumulation and aggregation has been the
focus for the other patients. There is a consensus that
a-synuclein turnover predominantly involves CMA.6,9,10
Factors that influence its processing via CMA including
various a-synuclein mutations and modifications including
oxidative damage and S129 phosphorylation21,22 can lead
to a-synuclein accumulation. We have recently reported
a decrease in the CMA proteins LAMP-2A and hsc70 in
PD brains,6 further suggesting a-synuclein aggregation
may be a consequence of its impaired degradation.
It is important to understand the cause of the decreased
LAMP-2A and hsc70 protein levels in PD brains to identify
where these changes should be placed in the overall disease
mechanisms.
Modeling the mitochondrial dysfunction, oxidative stress
and UPS dysfunction frequently reported in PD brains23 failed
to replicate the decrease in LAMP-2A or hsc70 levels seen
in PD brains, although a-synuclein levels were increased.
The increased a-synuclein levels observed with oxidative
stress and mitochondrial inhibition have been previously
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Figure 4 Analysis of PD brain samples and the dose-dependent impact of miRNA-373* upon LAMP-2A. Relative change in miRNAs normalized to actin mRNA levels and
compared with control in (a) SNc from PD patients and (b) the amygdala. (c) mRNA levels for lamp-2a, hsc70 and a-synuclein relative to actin mRNA and compared with
control values in PD amygdala and SNc. Data expressed as mean±S.E.M., controls (n¼ 5) and PD (n¼ 6). Statistical analyses compared with control group, *Po0.05.
(d) The influence of transfecting increasing concentrations of miRNA hsa-miR-373* into normal SH-SY5Y cells on LAMP-2A protein and mRNA levels 72 h after transfection.
The upper panel depicts the western blot of LAMP-2A levels relative to actin with increasing miR-373* levels, and the lower panel depicts the relationship between LAMP-2A
protein and lamp-2a mRNA levels relative to actin and normalized to untreated cells
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reported,24,25 and normal mRNA levels suggest this is a
consequence of impaired a-synuclein degradation. Conver-
sely, epoxomycin treatment led to an increase in the level
of a-synuclein, which was associated with a large increase in
mRNA. This increase was only seen in cells expressing
ectopic a-synuclein under the CMV promoter and not
observed in normal SH-SY5Y or melanoma cells that
express endogenous a-synuclein. This is in agreement
with a previous report demonstrating that epoxomycin
enhanced the expression of genes regulated by the CMV
promoter26 and therefore was an artifact of the system used.
In the absence of changes to LAMP-2A or hsc70 levels with
these treatments, the increased a-synuclein levels with
rotenone or paraquat were likely to be related to either an
inactivation of CMA or an impaired turnover of oxidatively
modified or S129 phosphorylated a-synuclein.21,22 We have
previously shown that increased a-synuclein levels per se did
not influence LAMP-2A or hsc70 protein levels,6 and we have
now confirmed that although increased oxidative stress and
mitochondrial dysfunction may interfere with a-synuclein
degradation, these are not predicted to lead to the decrease
in CMA proteins.
In recent years, the influence of miRNAs on the post-
transcriptional regulation of protein levels has received much
attention, in particular related to cancer initiation and
progression, with studies describing the downregulation of
miRNAs in cancer cells.27,28 More recently, several reports
have suggested that miRNA deregulation may play an
important role in various neurodegenerative disorders includ-
ing Alzheimer’s disease29 and spinocerebellar ataxia type 1.30
In PD, significant changes in the miRNA expression profile
have been reported with numerous miRNA precursors
elevated in the midbrain.13 We have focused on eight miRNAs
increased in PD brains that were strongly predicted to target
the 30UTR of either lamp-2a or hsc70. The luciferase reporter
constructs confirmed that four and three of these miRNAs
effectively targeted lamp-2a and hsc70 30UTRs, respectively,
suggesting they could underpin the decrease in hsc70 and
LAMP-2A reported in PD brains.6 We also demonstrated that
these miRNAs were able to cause a dose-dependent
decrease in endogenous LAMP-2A or hsc70 protein levels
in SHSY5Y cells. These decreases were not associated with
reduced mRNA levels, suggesting the miRNAs were acting at
the level of translational regulation.31 The associated
decrease in CMA would account for the decreased turnover
and accumulation of a-synuclein under these conditions, an
observation further supported by the lack of an increase
in a-synuclein mRNA levels. Our results demonstrated
that increases in specific miRNA levels, predicted to target
lamp-2a or hsc70, were sufficient to induce a-synuclein
accumulation in cell models.
The previously published changes to miRNA profiles in PD
were limited to a small number of samples,13 and therefore it
was important to replicate these changes in a larger cohort of
PD brain samples. We confirmed that of the seven miRNAs
capable of decreasing either LAMP-2A or hsc70 levels, six
miRNAs were markedly increased in PD SNc and more
mildly increased in the amygdala. Interestingly, the relative
increase in these miRNAs in SNc and amygdala paralleled the
relative decreases in hsc70 and LAMP-2A protein levels6 and
severity of LB pathology. There were marked decreases in
lamp-2a, hsc70 and a-synuclein mRNA levels in PD SNc,
which were milder in the amygdala. It has been suggested that
miRNAs can act via translational repression or increased
mRNA degradation.31 In the cell cultures, we found that as the
levels of miR-373* increased, there was an incremental
decrease in LAMP-2A protein levels, whereas lamp-2a mRNA
levels were only reduced at the higher miRNA concentrations.
This may help explain the greater decrease in lamp-2a and
hsc70 mRNA levels in PD SNc where the miRNA levels were
increased the most.
The decrease in a-synuclein mRNA levels in PD has
been previously reported.18,19 We noted that cells treated
with miR-106*a demonstrated a significant increase in
a-synuclein protein levels in association with decreased
mRNA levels, consistent with the observations seen in PD
brain samples. Interestingly, miR-106*a is predicted to
target the 30UTRs of both a-synuclein (miRBase Target
score 15.22) and hsc70 (miRBase Target score 17.39),
which may explain this observation. Other miRNAs may
also contribute to these effects in PD as both miR-7
and miR-153 have been previously demonstrated to
modulate a-synuclein expression in cell models32,33 and the
precursors of miR-7 were significantly increased in PD brain
samples.13
It is important to understand the cause of this deregulation
and if it relates to changes to the synthesis or stability of the
miRNAs in PD. The recent identification of a direct interaction
between the PD causing G2019S LRRK2 mutant with the
miRNA processing enzyme Argonaute2 and its effect upon
mRNA and protein levels reinforces the potential importance
of this pathway in PD.34
In conclusion, we demonstrated that in two brain regions
(SNc and amygdala) associated with PD a-synuclein pathol-
ogy, there were significant increases in specific miRNAs that
were predicted to target LAMP-2A and hsc70 expression.
These miRNAs were experimentally shown to decrease
LAMP-2A and hsc70 protein levels in cell culture and resulted
in significant a-synuclein intracellular accumulation. This
supports the hypothesis that elevated miRNA levels in
Parkinson’s disease brains will lead to the reported down-
regulation of LAMP-2A and hsc70 levels and compromised a-
synuclein degradation, adding a further dimension to the
pathogenesis of PD and LB formation. Modulation of CMA
function in PD by miRNA silencing might represent a suitable
target for drug intervention to modify the deleterious effects of
impaired protein handling.
Materials and Methods
Brain samples. Substantia nigra pars compacta and amygdala samples from
controls and patients with PD were obtained from the Navarra Brain Bank
(Pamplona, Spain) and used with the consent of the local ethics committee and
were part of a previous study.6 Controls had no clinical evidence ante mortem or
pathological evidence post mortem of any neurodegenerative disease. Patholo-
gical diagnoses of PD were made according to recognized criteria (Queen Square
Brain Bank criteria).
Cell cultures. The human SH-SY5Y neuroblastoma cell line (American Type
Culture Collection, Manassas, VA, USA) and SH-SY5Y clones constitutively
expressing full-length human WT a-synuclein with a C-terminal hemagglutinin tag
have been previously described.21 The human melanoma SK-MEL28 cell line
(American Type Culture Collection) was cultured in DMEM/F12 media
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supplemented with 10% FBS and penicillin/streptomycin. Other reagents were
obtained from Sigma Aldrich (Dorset, UK) or Merck (Nottingham, UK) unless
otherwise stated. Where stated, cells were treated for 48 h with rotenone (100 and
200 nM), paraquat (50 and 100mM) or epoxomycin (5 and 10 nM).
Western blot analysis. Cell samples were solubilized, separated on
NuPAGE Novex 4–12% Bis-Tris Gel (Invitrogen, Paisley, UK) and analyzed by
western blot as previously described6 using the following primary antibodies: anti-
a-synuclein (1 : 1000; Zymed, Invitrogen); anti-LAMP-2A (1 : 400); anti-hsc70
(1 : 500); and anti-b-actin (1 : 2000; all from Abcam, Cambridge, UK). Horseradish
peroxidase-conjugated anti-mouse or anti-rabbit IgG secondary antibodies (DAKO,
Ely, UK), were detected using ECL Plus Reagents and Hyperfilm ECL (GE
Healthcare, Little Chalfont, UK). Films were scanned and signals in the linear
range were quantified using DigiDoc software (Alpha Innotech, San Leandro, CA,
USA) and normalized to b-actin levels.
Luciferase reporter constructs. Luciferase targets were produced by
PCR amplification of the 30UTRs of lamp-2a and hsc70 from genomic DNA from
human embryonic kidney cells and ligating them into psiCheck2.2 (kind gift from
Dr. Marc Weinberg, University of Witwatersrand, Johannesburg, South Africa)
downstream of Renilla luciferase (Figure 2a) between XhoI and NotI sites as
previously described.35 The relevant NCBI accession numbers used to design
appropriate PCR primers were NM_006597.4 (HSPA8) and NM_002294.2
(LAMP2). The primers used for PCR were (XhoI hspa8 30UTR F) CATCTC-
GAGCCAACCAAGTGTAGATGTAG; (NotI hspa8 30UTR R) CATGCGGC
CGCATTGCATTTTCCACTTACAATAC; (XhoI lamp2a 30UTR F) CATCTCGAGAG
CAATTTTAGAATCTGCAACC; (NotI lamp2a 30UTR R) CATGCGGCCGCCATCTT
GAAGAAACAAGAGC. Mutations to the 30UTR sequences of the lamp2a and
hsc70 luciferase constructs were generated using Phusion Site-Directed
Mutagenesis Kit (Thermo Scientific, Loughborough, UK) and the following forward
primers (mutations in upper case); tcccagcatttCAagatcagtctt (miRNA 373*);
gcaatgttttaaggAAtatcttaagaagccc (miRNA 379); ggaaggaaataacaAAgcactttataaa-
cac (miRNA 106*a, miRNA 301b).
Treatment of cells with miRNAs. Cells were transfected using HiPerfect
Transfection reagent (Qiagen, Hilden, Germany) with miRNAs (Dharmacon,
Epsom, UK) listed in Table 1, up to 50 nM for 72 h to determine their optimal
concentrations. For long-term treatments, cells were transfected with 10 nM
miRNAs at 0, 3 and 6 days.
Luciferase assay. SH-SY5Y cells were transfected with 1mg of luciferase-
30UTR lamp-2a or luciferase-30UTR hsc70 plasmids and 1 ml of x-tremeGENE
HP transfection reagent (Roche, Burgess Hill, UK) as per the manufacturer’s
instructions in 24-well plates with 105 cells per well. At 4 h after transfection, cells
were treated with the miRNAs as described above. Luciferase activity was
measure after 48 h with Dual-Glo Luciferase Assay System (Promega,
Southampton, UK) using a luminometer (Synergy HT, Bio-Tek, Potton, UK).
Cell survival analysis. Cells were seeded in a 96-well plate and treated with
the toxin or miRNAs. Viable cell numbers were determined using the Celltiter Blue
kit (Promega) and expressed as a percentage of the control for each cell line.
Quantitative PCR. Total RNA was harvested using the RNeasy kit for cells or
miRNeasy kit for brain tissue (Qiagen) as per the manufacturer’s protocol. Only
samples with a low post-mortem delay (o11 h) were used and sample quality was
assessed by RNA Integrity Number (RIN).36 Reverse transcription (RT) was
performed with qSCRIP Reverse Transcriptase kit (Primer Design, Southampton,
UK) or TaqMan MicroRNA RT kit (Applied Biosystems, Carlsbad, CA, USA) as per
the manufacturer’s instructions. qPCR experiments were performed on a StepOne
Real-Time PCR system (Applied Biosystems) using Precision qPCR Mastermix or
TaqMan PCR (Applied Biosystems). TaqMan primers for the analysis of the
various miRNAs were obtained from Applied Biosystems, and primers for the
mRNA analysis are listed in Supplementary Table 2. Values were calculated using
the standard DDCt method.
Statistical analysis. Statistical analyses of the data were performed using
SPSS, program 16.0 (IBM, North Harbour Portsmouth, UK), using the
nonparametric Kruskal–Wallis test followed by the Mann–Whitney U-test.
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